Treatment Satisfaction and Quality of Life With Insulin Glargine Plus Insulin Lispro Compared With NPH Insulin Plus Unmodified Human Insulin in Individuals With Type 1 Diabetes
Open Access
- 1 June 2008
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (6) , 1112-1117
Abstract
OBJECTIVE—The purpose of this study was to compare quality of life (QoL) and treatment satisfaction using insulin glargine plus insulin lispro with that using NPH insulin plus unmodified human insulin in adults with type 1 diabetes managed with multiple injection regimens. RESEARCH DESIGN AND METHODS—As part of a 32-week, five-center, two-way crossover study in 56 individuals with type 1 diabetes randomized to evening insulin glargine plus mealtime insulin lispro or to NPH insulin (once or twice daily) plus mealtime unmodified human insulin, the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Audit of Diabetes Dependent Quality of Life questionnaire were completed at baseline and at weeks 16 and 32, with additional interim DTSQ measurements. RESULTS—For all patients combined, the mean baseline present QoL score was 1.3, reflecting “good” QoL. Present QoL improved with glargine + lispro but did not change with NPH + human insulin (1.6 ± 0.1 [mean ± SEM] vs. 1.3 ± 0.1, difference 0.3 [95% CI 0.1–0.6]; P = 0.014). Baseline mean average weighted impact score (AWI) of diabetes on QoL was −1.8, indicating a negative impact of diabetes on QoL. The AWI score at end point improved significantly with glargine + lispro but changed little with NPH + human insulin (−1.4 ± 0.1 vs. −1.7 ± 0.1, 0.3 [0.0–0.6]; P = 0.033). Treatment satisfaction (DTSQ 36-0 scale score) at end point was markedly greater with glargine plus lispro compared with that for NPH plus human insulin (32.2 ± 3.4 vs. 23.9 ± 7.2, 8.6 [6.5–10.6]; P < 0.001). CONCLUSIONS—Insulin glargine plus insulin lispro improves treatment satisfaction, reduces the negative impact of diabetes on QoL, and improves QoL in comparison with NPH insulin plus unmodified human insulin in type 1 diabetes.Keywords
This publication has 20 references indexed in Scilit:
- Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetesDiabetic Medicine, 2006
- Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulinDiabetic Medicine, 2004
- Effect of the rapid‐acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetesDiabetic Medicine, 2003
- Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at MealtimeDiabetes Care, 2003
- Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trialBMJ, 2002
- Patient perceptions of diabetes and diabetes therapy: assessing quality of lifeDiabetes/Metabolism Research and Reviews, 2002
- Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trialDiabetic Medicine, 2000
- Diabetes Mellitus1998
- Psychological issues in clinical trial designThe Irish Journal of Psychology, 1997
- Measures of Psychological Well‐being and Treatment Satisfaction Developed from the Responses of People with Tablet‐treated DiabetesDiabetic Medicine, 1990